ArticleLife (Basel, Switzerland)2026
Vimentin in Developing Human Adrenal Medulla Cells.
Article in Life (Basel, Switzerland), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
The development of the human adrenal gland involves dramatic structural reorganization, including migration of adrenal medulla cells, changes in cell shape, and complex dynamics of distinct cell populations. These processes require dynamic remodeling of the cytoskeleton. In this study, we investigated vimentin-a key regulator of cell shape changes-in a population of developing adrenal medulla cells, which we call large cells (LCs). We performed double immunofluorescence for tyrosine hydroxylase and vimentin on adrenal glands from human fetuses aged from 8 gestational weeks to 11 days postnatally and compared our findings with recently published single-cell transcriptomics data. We found that the ratio of vimentin-positive LCs did not change significantly with age, and staining intensity was even higher in later fetuses, indicating that vimentin immunoreactivity does not decline with age. In contrast, analysis of the scRNA-seq dataset revealed a decrease in the proportion of vimentin-positive cells within the subpopulation of late chromaffin cells. We attribute these differences to both the high stability of vimentin filaments relative to their short-lived mRNA and the physiological heterogeneity of developing chromaffin cells, the precise causes of which remain to be determined.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.